{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:08:15Z","timestamp":1790096895202,"version":"4.0.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drudis.2026.104787","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T06:22:24Z","timestamp":1787552544000},"page":"104787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Signaling execution readiness: The evolving leadership requirements for biotech fundraising"],"prefix":"10.1016","volume":"31","author":[{"given":"Keita","family":"Kiriya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6701-9828","authenticated-orcid":false,"given":"Sotaro","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104787_b0005","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s43441-021-00364-y","article-title":"Valuation and returns of drug development companies: lessons for bioentrepreneurs and investors","volume":"56","author":"Michaeli","year":"2022","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.drudis.2026.104787_b0010","unstructured":"World Intellectual Property Organization (WIPO). Intellectual property valuation in biotechnology and pharmaceuticals \u2013 4 the real options method. Accessed 29 July 2026. https:\/\/www.wipo.int\/web-publications\/intellectual-property-valuation-in-biotechnology-and-pharmaceuticals\/en\/4-the-real-options-method.html."},{"key":"10.1016\/j.drudis.2026.104787_b0015","unstructured":"Ernst & Young. Biotech beyond borders. EY website. Published 2026. Accessed 29 July 2026. https:\/\/www.ey.com\/en_us\/life-sciences\/biotech-outlook; https:\/\/www.biopharmiq.com\/post\/2025-full-year-bio-pharma-private-funding-trends; 2026."},{"key":"10.1016\/j.drudis.2026.104787_b0020","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.respol.2014.11.011","article-title":"Quality signals? The role of patents, alliances, and team experience in venture capital financing","volume":"44","author":"Hoenig","year":"2015","journal-title":"Res Policy"},{"key":"10.1016\/j.drudis.2026.104787_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/smj.495","article-title":"Stacking the deck: the effects of top management backgrounds on investor decisions","volume":"27","author":"Higgins","year":"2006","journal-title":"Strateg Manag J"},{"key":"10.1016\/j.drudis.2026.104787_b0030","unstructured":"FIERCE Biotech. Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new funds. Published 19 December 2025. Accessed 29 July 2026. https:\/\/www.fiercebiotech.com\/biotech\/fierce-biotech-fundraising-tracker-25."},{"key":"10.1016\/j.drudis.2026.104787_b0035","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0048-7333(03)00107-0","article-title":"Critical junctures in the development of university high-tech spinout companies","volume":"33","author":"Vohora","year":"2004","journal-title":"Res Policy"},{"key":"10.1016\/j.drudis.2026.104787_b0040","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.respol.2007.02.022","article-title":"Experienced entrepreneurial founders, organizational capital, and venture capital funding","volume":"36","author":"Hsu","year":"2007","journal-title":"Res Policy"},{"key":"10.1016\/j.drudis.2026.104787_b0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1287\/orsc.1070.0311","article-title":"Founding the future: path dependence in the evolution of top management teams from founding to IPO","volume":"19","author":"Beckman","year":"2008","journal-title":"Organ Sci"},{"key":"10.1016\/j.drudis.2026.104787_b0050","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/nrd3251","article-title":"The importance of new companies for drug discovery: origins of a decade of new drugs","volume":"9","author":"Kneller","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104787_b0055","article-title":"Structure and ingenuity of ecosystem formation in life science \u2013 system formation in Belgium and challenges in Japan","volume":"44","author":"Aoyama","year":"2023","journal-title":"DBJ Econ Today"},{"key":"10.1016\/j.drudis.2026.104787_b0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1287\/orsc.2017.1110","article-title":"Failure is an option: institutional change, entrepreneurial risk, and new firm growth","volume":"28","author":"Eberhart","year":"2017","journal-title":"Organ Sci"},{"key":"10.1016\/j.drudis.2026.104787_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.respol.2020.104062","article-title":"Different founders, different venture outcomes: a comparative analysis of academic and non-academic startups","volume":"49","author":"Roche","year":"2020","journal-title":"Res Policy"},{"key":"10.1016\/j.drudis.2026.104787_b0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1287\/orsc.14.2.149.14995","article-title":"Founder-CEO succession and the paradox of entrepreneurial success","volume":"14","author":"Wasserman","year":"2003","journal-title":"Organ Sci"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:15:21Z","timestamp":1790093721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1359644626001923"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104787","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Signaling execution readiness: The evolving leadership requirements for biotech fundraising","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104787"}}